CLSI M Quality Control for Commercial Microbial Identification Systems; Approved Guideline. Final document was approved through the CLSI voting process. – Publication of CLSI M Quality Control for. Commercial Microbial. Buy CLSI M50 A Ed. 1 () Quality Control For Commercial Microbial Identification Systems from SAI Global.

Author: Vudogami Tojaktilar
Country: Mozambique
Language: English (Spanish)
Genre: Video
Published (Last): 20 February 2011
Pages: 231
PDF File Size: 8.11 Mb
ePub File Size: 6.44 Mb
ISBN: 936-7-40863-975-8
Downloads: 54665
Price: Free* [*Free Regsitration Required]
Uploader: Zugrel

Performance standards for antimicrobial susceptibility testing; 25th informational supplement. These data demonstrated that retesting of many types of commercially prepared microbiological culture media with QC strains in-house will not improve the quality of patient results.

Standards Subscriptions from ANSI provides a money-saving, multi-user solution for accessing standards. September 25, Content source: Similarly, testing commercially prepared exempt media with QC strains will not prevent a technologist from choosing a poor quality portion of a sputum sample for plating onto a blood agar plate.

National Center for Biotechnology InformationFlsi. Need more than one copy? For example, daily QC testing with antimicrobial susceptibility tests will not prevent a laboratory from reporting results from a mixed population of organisms.

The frequency of errors can be determined by reviewing historical data; however, the accurate determination of patient harm resulting from these errors is highly variable and a nearly impossible task. Prepublished online Oct 7. Again, following the CLSI statistically based standard for antimicrobial susceptibility QC testing should be sufficient, and it is unclear how the development of an IQCP will improve the quality flsi reporting patients’ results.

  ASTM F963-08 PDF

Please review our privacy policy. You may delete a document from your Alert Profile at any time.

CLSI MA – Quality Control for Commercial Microbial Identification Systems; Approved Guideline

The streamlined M50a- approach was developed following an evaluation of data provided by the American Society for Microbiology for a survey conducted to determine the QC failure rates of commercial MISs. Clinical and Laboratory Standards Institute. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.

Notes The views expressed in this Commentary do not necessarily reflect the views of the journal or of ASM. Add to Alert PDF. Likewise, daily external QC of self-contained molecular test systems that have internal controls also does not mitigate the risk of cartridge-specific errors or inadequate specimen collection.

These two m500-a would apply to all nonwaived tests and would become effective on 1 January However, there were concerns expressed by some in industry and in laboratories, as well as by other experts, about the rigidity and the limit of scope with EQC.

EQC primarily refers to those test systems that utilize internal controls.

Clinical Laboratory Improvement Advisory Committee (CLIAC)

Subscription pricing is determined by: To receive email updates about this page, enter your email address: Quality control for commercial microbial identification systems.


The views expressed in this Commentary do not necessarily reflect the views of the journal or of ASM. It is anticipated that MA will be used extensively in the United Cclsi and internationally to reduce resources spent on excessive QC testing.

Support Center Support Center. Please first log in with a verified email before subscribing to alerts. CMS stated that this action had nothing to do with the implementation of IQCP but was due to the fact that the CLSI documents must be purchased and are not freely available to the public.

Individualized Quality Control Plan (IQCP): Is It Value-Added for Clinical Microbiology?

cclsi Errors in laboratory medicine can certainly have significant effects on patient care, and we in the clinical microbiology community clearly support quality improvement measures which have the potential to positively impact patient outcomes.

These data showed that the failure rate due to the MIS itself was less than 0. This article has been cited by other clei in PMC. Registration is now closed. Generally, CLIA ’67 affected large hospital and independent laboratories, while physician office laboratories and small laboratories were essentially left unregulated.